Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2007

View Archived Issues

Human fibroblast growth factor safe, active in coronary artery disease patients

Prolonged renal effects seen with AlbuBNP in dogs

Sitaxsentan assessed as a possible treatment for Eisenmenger's syndrome

Combination therapy with lapaquistat and atorvastatin improves hypercholesterolemia

Bioponic launches Curemisinin for the treatment of malaria in Africa

Preclinical profile of Merck & Co.'s novel NR2B-selective NMDA antagonist

Neuroprotection by small-molecule Hedgehog agonist in an in vitro model of ischemia

Provectus begins phase II clinical trial for psoriasis

VaxGen and Raven announce definitive merger agreement

Novel antiatherosclerotic agents emerge from Merck & Co. R&D

Final positive results announced from phase II GHRH trial

New data for mipomersen in routine high cholesterol patients

MedImmune and Infinity initiate phase II clinical trial of IPI-504 for prostate cancer

Novexel initiates phase II clinical trial of NXL-103 for community-acquired pneumonia

Karo Bio initiates phase IIb clinical study of KB-2115 for dyslipidemia

Avax initiates phase III clinical study of M-Vax in metastatic melanoma

AEterna Zentaris completes patient enrollment in phase II trial of perifosine

Northwestern University initiates enrollment in phase IIb study of Nexavar

New agents for treating neurological disorders disclosed in recent patent literature

Ceregene completes enrollment in phase II clinical trial of CERE-120 for Parkinson's disease

Amylin reports positive results from phase IIa study of pramlintide and metreleptin

The Juvenile Diabetes Research Foundation and Lilly fund research in diabetes biomarkers

CHMP gives positive approval for Avastin for the first-line treatment of renal cell carcinoma

Pfizer acquires Coley Pharmaceutical Group

CHMP gives positive opinion for Abbott's Humira in treatment of moderate to severe plaque psoriasis

FDA approves Seroquel XR for maintenance treatment of schizophrenia

Tibotec initiates phase II trial of telaprevir in treatment-naive chronic hepatitis C patients

Novel small-molecule compound appears to extend L-DOPA antiparkinsonian effects

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...